AxoGen, Inc (NASDAQ:AXGN) Director Quentin S. Blackford bought 1,365 shares of AxoGen stock in a transaction that occurred on Friday, August 9th. The stock was purchased at an average cost of $13.10 per share, for a total transaction of $17,881.50. Following the acquisition, the director now owns 25,098 shares of the company’s stock, valued at $328,783.80. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

AXGN stock opened at $14.85 on Thursday. The company has a current ratio of 8.70, a quick ratio of 7.87 and a debt-to-equity ratio of 0.02. AxoGen, Inc has a twelve month low of $11.82 and a twelve month high of $46.25. The business’s 50 day moving average is $18.24. The firm has a market capitalization of $573.52 million, a PE ratio of -27.50 and a beta of 0.18.

AxoGen (NASDAQ:AXGN) last released its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.09. AxoGen had a negative net margin of 26.91% and a negative return on equity of 16.73%. The company had revenue of $26.70 million for the quarter, compared to analysts’ expectations of $26.77 million. During the same quarter last year, the company earned ($0.09) earnings per share. The firm’s revenue for the quarter was up 29.7% on a year-over-year basis. On average, equities analysts predict that AxoGen, Inc will post -0.72 EPS for the current year.

Several analysts recently weighed in on the stock. ValuEngine raised shares of AxoGen from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. BidaskClub cut shares of AxoGen from a “sell” rating to a “strong sell” rating in a report on Wednesday, July 24th. JMP Securities cut their price objective on shares of AxoGen from $43.00 to $28.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. Canaccord Genuity set a $30.00 price objective on shares of AxoGen and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, Cantor Fitzgerald cut their price objective on shares of AxoGen from $30.00 to $21.00 and set an “overweight” rating on the stock in a report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $31.00.

A number of hedge funds have recently added to or reduced their stakes in the business. William Blair Investment Management LLC acquired a new position in shares of AxoGen in the 2nd quarter valued at $9,529,000. Frontier Capital Management Co. LLC acquired a new position in shares of AxoGen in the 1st quarter valued at $7,402,000. Baillie Gifford & Co. increased its holdings in shares of AxoGen by 54.0% in the 1st quarter. Baillie Gifford & Co. now owns 980,700 shares of the medical equipment provider’s stock valued at $20,654,000 after acquiring an additional 343,900 shares during the period. D. E. Shaw & Co. Inc. increased its holdings in shares of AxoGen by 89.8% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 601,118 shares of the medical equipment provider’s stock valued at $11,902,000 after acquiring an additional 284,479 shares during the period. Finally, Point72 Asset Management L.P. increased its holdings in shares of AxoGen by 75.9% in the 2nd quarter. Point72 Asset Management L.P. now owns 595,084 shares of the medical equipment provider’s stock valued at $11,783,000 after acquiring an additional 256,697 shares during the period. 87.46% of the stock is currently owned by institutional investors.

About AxoGen

AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Featured Article: How to interpret Moving Average Convergence Divergence (MACD)

Insider Buying and Selling by Quarter for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.